Veracyte (NASDAQ:VCYT) Shares Unloaded Rep. Gilbert Ray Cisneros, Jr.

Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Veracyte, Inc. (NASDAQ:VCYT). In a filing disclosed on December 15th, the Representative disclosed that they had sold between $1,001 and $15,000 in Veracyte stock on November 12th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Spotify Technology (NYSE:SPOT) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of Alphabet (NASDAQ:GOOGL) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of First Watch Restaurant Group (NASDAQ:FWRG) on 11/26/2025.
• Purchased $1,001 – $15,000 in shares of TKO Group (NYSE:TKO) on 11/26/2025.
• Sold $1,001 – $15,000 in shares of RBC Bearings (NYSE:RBC) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Stifel Financial (NYSE:SF) on 11/24/2025.
• Purchased $1,001 – $15,000 in shares of Logan Energy (CVE:LGN) on 11/24/2025.
• Sold $1,001 – $15,000 in shares of Primoris Services (NASDAQ:PRIM) on 11/24/2025.
• Purchased $15,001 – $50,000 in shares of LandBridge (NYSE:LB) on 11/21/2025.
• Purchased $50,001 – $100,000 in shares of LandBridge (NYSE:LB) on 11/20/2025.

Veracyte Stock Up 2.1%

VCYT stock traded up $0.88 during midday trading on Friday, reaching $42.92. The company’s stock had a trading volume of 1,159,960 shares, compared to its average volume of 903,586. Veracyte, Inc. has a 52 week low of $22.61 and a 52 week high of $50.71. The business’s 50-day simple moving average is $40.91 and its 200-day simple moving average is $33.07. The stock has a market cap of $3.39 billion, a PE ratio of 112.95 and a beta of 1.83.

Veracyte (NASDAQ:VCYT) last released its quarterly earnings data on Tuesday, November 4th. The biotechnology company reported $0.51 EPS for the quarter, beating analysts’ consensus estimates of $0.32 by $0.19. The business had revenue of $131.87 million during the quarter, compared to analysts’ expectations of $124.62 million. Veracyte had a net margin of 6.12% and a return on equity of 7.23%. The firm’s quarterly revenue was up 13.8% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.33 EPS. As a group, equities analysts forecast that Veracyte, Inc. will post 0.68 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the company. Morgan Stanley lifted their price objective on Veracyte from $40.00 to $48.00 and gave the company an “underweight” rating in a report on Monday, December 1st. Wall Street Zen lowered shares of Veracyte from a “strong-buy” rating to a “buy” rating in a research note on Saturday, December 13th. Canaccord Genuity Group increased their price objective on shares of Veracyte from $40.00 to $43.00 and gave the stock a “hold” rating in a research report on Wednesday, November 5th. Weiss Ratings restated a “hold (c)” rating on shares of Veracyte in a report on Monday. Finally, UBS Group upped their target price on shares of Veracyte from $42.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Veracyte presently has a consensus rating of “Moderate Buy” and an average price target of $45.43.

Insider Activity at Veracyte

In other news, insider John Leite sold 1,278 shares of the business’s stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $47.51, for a total value of $60,717.78. Following the completion of the sale, the insider owned 82,113 shares of the company’s stock, valued at approximately $3,901,188.63. The trade was a 1.53% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Annie Mcguire sold 10,739 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $43.13, for a total transaction of $463,173.07. Following the transaction, the senior vice president directly owned 67,760 shares in the company, valued at approximately $2,922,488.80. This represents a 13.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 142,984 shares of company stock valued at $6,282,692. 1.40% of the stock is currently owned by insiders.

Institutional Trading of Veracyte

A number of hedge funds have recently modified their holdings of the stock. Champlain Investment Partners LLC bought a new position in Veracyte in the 3rd quarter valued at about $40,064,000. Nuveen LLC bought a new position in shares of Veracyte during the first quarter worth approximately $33,003,000. Artisan Partners Limited Partnership lifted its holdings in Veracyte by 20.7% during the 2nd quarter. Artisan Partners Limited Partnership now owns 6,321,775 shares of the biotechnology company’s stock worth $170,878,000 after purchasing an additional 1,082,064 shares during the last quarter. Squarepoint Ops LLC boosted its stake in Veracyte by 770.6% in the 2nd quarter. Squarepoint Ops LLC now owns 897,387 shares of the biotechnology company’s stock valued at $24,256,000 after purchasing an additional 794,307 shares during the period. Finally, Fred Alger Management LLC acquired a new position in Veracyte in the 3rd quarter valued at $26,348,000.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

Veracyte Company Profile

Veracyte, Inc is a genomic diagnostics company focused on improving diagnostic accuracy and patient care through advanced molecular testing. Founded in 2008 and headquartered in South San Francisco, California, the company develops and commercializes minimally invasive genomic tests that aid in the diagnosis of thyroid, lung and other diseases. Veracyte’s proprietary platform analyzes gene expression patterns in clinical samples to help physicians make more informed treatment decisions, reducing unnecessary surgeries and improving patient outcomes.

The company’s flagship product, the Afirma Genomic Sequencing Classifier, is designed to assess thyroid nodules with indeterminate cytology, helping clinicians distinguish benign from suspicious nodules.